drugset / Trial / NCT04612972
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
Phase 3
Completed
12000 enrolled
Universidad Peruana Cayetano Heredia
National University of San Marcos, Peru · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.
Timeline
- Start
- 2020-09-09
- Primary completion
- 2021-02-19
- Completion
- 2023-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inactivated SARS-CoV-2 vaccine (Vero cell) | Vaccine | 4 ug | Intramuscular |
| Subject | Inactivated SARS-CoV-2 vaccine (Vero cell) | Vaccine | 200 unknown | Intramuscular |